US House "yes" and "no" to Rx re-imports

16 July 2001

The US House of Representatives has rejected a bill to let companiesre-import back into the USA Food and Drug Administration-approved drugs from overseas, but has also approved mail-order purchases of such products from abroad by individuals for their own use.

The House voted 267-159 against an amendment to the fiscal 2002 spending bill of the Department of Agriculture and the FDA, proposed by Vermont Independent Representative Bernie Sanders, to allow companies to re-import. Last year, it backed a similar bill from Rep Sanders by 363 votes to 12. The "personal use" amendment to the spending bill, from Republican Representative Gil Gutknecht, passed on a 324-101 vote.

The votes came a day after Health and Human Services Secretary Tommy Thompson reaffirmed the opinion of his predecessor in the Clinton administration, Donna Shalala, that the re-import law could not be implemented because guarantees that it would lower prices to consumers and protect the safety of the drug supply could not be given (Marketletters January 1 & 8 and July 16).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight